[1] [1] HUANG Y W, HSU C W, LU S N, et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B[J]. Hepatol Int, 2020, 14(6): 997-1008.

[2] [2] WANG Y X, NIKLASCH M, LIU T T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72(5): 865-876.

[3] [3] STADLER D, KCHELE M, JONES A N, et al. Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20[J]. Embo Rep, 2021, 22(6): e49568.

[4] [4] ALLWEISS L, GIERSCH K, PIROSU A, et al. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genomein vivo[J]. Gut, 2022, 71(2): 372-381.

[5] [5] YANG Z J, SUN B Z, XIANG J C, et al. Role of epigenetic modification in interferon treatment of hepatitis B virus infection[J]. Front Immunol, 2022, 13: 1018053.

[6] [6] GAN W Q, GAO N, GU L, et al. Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure[J]. J Clin Transl Hepato, 2023, 11(2): 314-322.

[7] [7] ZHONG S, LI Q, WEN C, et al. Interferon alpha facilitates anti-HBV cellular immune response in a B cell-dependent manner[J]. Antiviral Res, 2022, 207: 105420.

[8] [8] LIU Y, HU X, HU X, et al. T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production[J]. J Gastroenterol, 2022, 57 (1): 30-45.

[9] [9] ZHOU Y, ZHONG S H, TANG L B, et al. Interferon alpha-induced CXCL13 and IL-6 from intrahepatic monocytes facilitate HBV antigen seroconversion in chronic HBV infection[J]. J Hepatol, 2020, 73: S581.

[10] [10] LEE S K, KWON J H, LEE S W, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294.

[11] [11] LIU J Y, WANG T Y, ZHANG W, et al. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and Meta-analysis[J]. Hepatol Int, 2020, 14(6): 958-972.

[12] [12] MO Z, XIE D, FU L, et al. Functional cure based on pegylated interferon ɑ-2b therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-4 years data update[J]. Hepatology, 2022, 76: S24-S25.

[13] [13] MICCO L, PEPPA D, LOGGI E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B[J]. J Hepatol, 2013, 58(2): 225-233.

[14] [14] LAI C L, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66(2): 275-281.

[15] [15] TAN A T, HOANG L T, CHIN D, et al. Reduction of HBV replication prolongs the early immunological response to IFN therapy[J]. J Hepatol, 2014, 60(1): 54-61.

[16] [16] LI M, SUN F, BI X, et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients[J]. Virol Sin, 2022, 37(3): 390-397.

[17] [17] LIU Y, REN S, MA L, et al. Peg-IFNalpha combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function[J]. Virol J, 2024, 21(1): 77.

[18] [18] JIA H Y, YU G D, YU J, et al. Immunomodulatory and antiviral therapy improved functional cure rate in CHB patients with high HBsAg level experienced NA[J]. J Clin Transl Hepato, 2023, 11(5): 1003-1010.

[19] [19] WANG D, FU B, SHEN X, et al. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-alpha therapy[J]. Signal Transduct Target Ther, 2021, 6(1): 376.

[20] [20] LAMPERTICO P, ROULOT D, WEDEMEYER H. Bulevirtide with or without pegIFN for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies[J]. J Hepatol, 2022, 77(5): 1422-1430.

[21] [21] BUTI M, HEO J, TANAKA Y, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B[J]. J Hepatol, 2024, 82(2): 222-234.

[22] [22] YUEN M F, LIM Y S, YOON K T, et al. VIR-2218(elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024, 9(12): 1121-1132.

[23] [23] HOU J L, XIE Q, ZHANG W H, et al. Efficacy and safety of xalnesiran combination therapies with and without an immunomodulator in virologically-suppressed participants with chronic hepatitis B: primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (Piranga)[J]. Hepatology, 2024, 79(2): E39-E40.

[24] [24] HOU J, GANE E, BALABANSKA R, et al. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients[J]. Clin Mol Hepatol, 2024, 30(2): 191-205.

[25] [25] BAZINET M, PNTEA V, PLACINTA G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naive to Nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158(8): 2180-2194.

[26] [26] WU Y, LIU Y, LU J, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance[J]. Clin Gastroenterol Hepatol, 2020, 18(2): 514-516.e2.

[27] [27] GAO N, GUAN G, XU G, et al. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HB-sAg-positive patients with functional cure following PEG-IFN-based therapy[J]. Aliment Pharmacol Ther, 2023, 58(10): 1086-1098.

[28] [28] ZHANG M, LI G, SHANG J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study[J]. Hepatol Int, 2020, 14(2): 212-224.

[29] [29] FARAG M S, van CAMPENHOUT M J H, PFEFFERKORN M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B[J]. Clin Infect Dis, 2021, 72(2): 202-211.

[30] [30] BRAKENHOFF S M, de MAN R A, BOONSTRA A, et al. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss[J]. Aliment Pharmacol Ther, 2021, 53(2): 314-320.

[31] [31] VECCHI A, ROSSI M, TIEZZI C, et al. HBcrAg values may predict virological and immunological responses to pegIFN-alpha in NUC-suppressed HBeAg-negative chronic hepatitis B[J]. Gut, 2024, 73(10): 1737-1748.

[32] [32] BEUDEKER B J, GROOTHUISMINK Z M, de MAN R A, et al. Hepatitis B core-related antigen levels predict pegylated interferon- therapy response in HBeAg-positive chronic hepatitis B[J]. Antivir Ther, 2020, 25(4): 217-222.

[33] [33] HUANG D, WU D, WANG P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB[J]. J Hepatol, 2022, 77(1): 42-54.

[34] [34] RINKER F, BREMER C M, SCHRDER K, et al. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a[J]. Liver Int, 2020, 40(2): 324-332.

[35] [35] PFEFFERKORN M, SCHOTT T, BHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292.

[36] [36] LAZAREVIC I, MILJANOVIC D, BANKO A, et al. Quantitative HBV core antibodies as a prognostic marker for HBeAg seroclearance: a systematic review with Meta-analysis[J]. Viruses, 2024, 16(7): 1121.

[37] [37] WANG J, ZHANG Z, ZHU L, et al. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B[J]. Virulence, 2024, 15(1): 2404965.

[39] [39] WANG W X, JIA R, GAO Y Y, et al. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN- in NA-suppressed chronic hepatitis B patients[J]. Front Immunol, 2022, 13: 894410.

[40] [40] WU Y, WANG X, LIN X, et al. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance[J]. J Microbiol Immunol Infect, 2021, 54(2): 238-244.

[42] [42] CAO W, XIE S, ZHANG L, et al. Expression of functional molecule on plasmacytoid dendritic cells is associated with HBsAg loss in HBeAg-positive patients during PEG-IFN -2a treatment[J]. Front Immunol, 2022, 13: 891424.

[43] [43] CAO W, LU H, ZHANG L, et al. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN -2a therapy[J]. Front Immunol, 2022, 13: 1067362.

[44] [44] WU Z Q, TAN L, GAN W Q, et al. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-[J]. Ann Transl Med, 2021, 9(5): 414.

[45] [45] XIONG S, ZHU D, LIANG B, et al. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss[J]. EBioMedicine, 2021, 69: 103464.

[46] [46] XU Z, LIN J Z, ZENG Y F, et al. Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure[J]. J Med Virol, 2021, 93(8): 4966-4974.

[47] [47] WANG P, MO Z, ZHANG Y, et al. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon[J]. Front Immunol, 2022, 13: 1104329.

[48] [48] WU L L, LI X Y, DENG H, et al. Transforming growth factor-: an early predictor of a functional cure in chronic hepatitis B treated with interferon[J]. Virus Res, 2022, 309: 198657.

[49] [49] CHEN X, ZHANG B, SONG X, et al. Serum sPD-1 and sPDL1 as predictive biomarkers for HBsAg clearance in HBeAgnegative CHB patients undergoing IFN-based therapy[J]. Aliment Pharmacol Ther, 2024, 60(5): 593-603.

[50] [50] XUN Z, LIN J, YU Q, et al. Taurocholic acid inhibits the response to interferon- therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function[J]. Cell Mol Immunol, 2021, 18(2): 461-471.

[53] [53] PATEL N H, LUCKO A, VACHON A, et al. Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease[J]. J Viral Hepat, 2024, 31(10): 582-591.

[54] [54] LIU Y, ZHENG Y, LIN X, et al. Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha[J]. BMC Endocr Disord, 2023, 23(1): 115.